Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds

• Type: Article in International Scientific Journal
• Date: 2020-04-10

Authors

Maria João Ramalho (Author) FEUP; Stephanie Andrade (Author) FEUP; Joana Angélica Loureiro (Author) FEUP; Maria do Carmo Pereira (Author) FEUP

Journal

Title: Drug Delivery and Translational Research

Vol. 10 No. 2

Pages: 380-402

ISSN: 2190-393X

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 0 Citations

ISI Web of Science

Scopus - 15 Citations

Other information

Authenticus ID: P-00R-FDD

DOI: 10.1007/s13346-019-00694-3

Abstract (EN): Alzheimer’s disease (AD) is a form of dementia with high impact worldwide, accounting with more than 46 million cases. It is estimated that the number of patients will be four times higher in 2050. The initial symptoms of AD are almost imperceptible and typically involve lapses of memory in recent events. However, the available medicines still focus on controlling the symptoms and do not cure the disease. Regarding the advances in the discovery of new treatments for this devastating disease, natural compounds are gaining increasing relevance in the treatment of AD. Nevertheless, they present some limiting characteristics such as the low bioavailability and the low ability to cross the blood-brain barrier (BBB) that hinder the development of effective therapies. To overcome these issues, the delivery of natural products by targeting nanocarriers has aroused a great interest, improving the therapeutic activity of these molecules. In this article, a review of the research progress on drug delivery systems (DDS) to improve the therapeutic activity of natural compounds with neuroprotective effects for AD is presented. [Figure not available: see fulltext.]. © 2019, Controlled Release Society.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 23